POSB109 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin with Bendamustine and Rituximab vs. Bendamustine and Rituximab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Abstract
Authors
M Bellone L Pradelli A Caputo D Ghislieri A Launonen R Ho